An interventional study of Garcinia cambogia rind powder and Garcinia cambogia rind powder in Lipid Profile, sponsored by University of Lahore. Completed at 1 site in Pakistan. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-18.
Sponsored by University of Lahore · Not applicable, Interventional, and Health services research
Garcinia cambogia, rich in hydroxycitric acid (HCA), has been suggested to promote weight loss and improve metabolic parameters. Evidence regarding its efficacy in pre-diabetic obese adults remains limited.
Objective: To evaluate the effects of Garcinia cambogia rind powder supplementation on anthropometric, glycemic, lipid, hepatic, and renal parameters in pre-diabetic obese adults.
The observed effects are likely mediated by HCA, which inhibits ATP-citrate lyase, reducing de novo lipogenesis, enhancing glucose utilization, and modulating adipokines and oxidative stress.
Conclusion: Garcinia cambogia rind powder supplementation exerts dose-dependent metabolic benefits in pre-diabetic obese adults, improving anthropometric, glycemic, lipid, hepatic, and renal parameters without adverse effects. It may serve as a complementary intervention alongside lifestyle modification for the management of obesity and pre-diabetes.
778 studies on the registry are indexed under Glucose Intolerance; 129 are open to participants now.
This study's enrollment of 90 is above the median of 60 across 645 interventional studies indexed under Glucose Intolerance.
Browse Glucose Intolerance studies →University of Lahore is the lead sponsor of 223 studies on the registry; 40 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Starch capsule once a day
Dietary Supplement: Garcinia cambogia rind powder
100mg/day of Garcinia cambogia rind powder
Dietary Supplement: Garcinia cambogia rind powder
200mg/day of Garcinia cambogia rind powder
Dietary Supplement: Garcinia cambogia rind powder
Once a day
Once a day for 12 weeks
Weight
Time frame: 12 weeks
Lipid profile
Time frame: 12 weeks
fasting glucose
Time frame: 12 weeks
Plan to share: No
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Lahore